Company / Shareholders' Equity
Viridian Therapeutics, Inc.\DE Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$722.2M
FY2025
5-year range
$187.7M / $722.2M
FY2021-FY2025
Trend
+7.5%
vs FY2024
Sector context
#62 of 213
Health Care
What the data says
At $722M, Viridian Therapeutics, Inc.\DE's shareholders' equity ranks #62 of 213 in the Health Care sector. Shareholders' Equity has increased for 6 consecutive years, from $16M in FY2019 to $722M in FY2025.
Based on SEC 10-K filings.
$722M in FY2025 with a 5-year CAGR of +43.2%.
Improved from $442M to $722M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +22.3%
- 5-Year CAGR
- +43.2%
- 10-Year CAGR
- -
Sector benchmark
#62 of 213 in Health CareTop 29% of 213This company $722.2M Sector average $2.5B
▼
-71.7% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's shareholders' equity has grown for 6 consecutive years.
- 5-year CAGR of +43.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 7.5% year-over-year.
- Ranks #62 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $722.2M | +7.5% |
| FY2024 | $671.6M | +51.9% |
| FY2023 | $442.0M | +11.9% |
| FY2022 | $395.1M | +110.5% |
| FY2021 | $187.7M | +56.4% |
| FY2020 | $120.0M | +661.9% |
| FY2019 | $15.8M | -69.3% |
| FY2018 | $51.3M | +33.3% |
| FY2017 | $38.5M | +162.2% |
| FY2016 | -$61.9M | -36.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026